Abstract
Dual-modality contrast agents, such as radiolabeled nanoparticles, are promising candidates for a number of diagnostic applications, since they combine the advantages of two different imaging modalities, namely SPECT or PET imaging with MR imaging. The benefit of such a combination is to more accurately interpret disease and abnormalities in vivo, by exploiting the advantages of each imaging technique, i.e. high sensitivity for SPECT/PET, high resolution anatomical information for MRI. In this review article, we provide an overview of recent findings in the synthesis, evaluation and application of radiolabeled iron oxide nanoparticles as dual-modality SPECT/MRI and PET/MRI imaging probes.
MeSH terms
-
Antibodies / chemistry
-
Antineoplastic Agents / chemistry
-
Contrast Media* / chemistry
-
Contrast Media* / therapeutic use
-
Ferric Compounds* / chemistry
-
Humans
-
Isotope Labeling
-
Magnetic Resonance Imaging / instrumentation
-
Magnetic Resonance Imaging / methods
-
Magnetite Nanoparticles* / chemistry
-
Magnetite Nanoparticles* / therapeutic use
-
Neoplasms / diagnosis*
-
Neoplasms / diagnostic imaging
-
Neoplasms / radiotherapy*
-
Peptides / chemistry
-
Positron-Emission Tomography / instrumentation
-
Positron-Emission Tomography / methods
-
Radioisotopes / chemistry
-
Tomography, Emission-Computed, Single-Photon / instrumentation
-
Tomography, Emission-Computed, Single-Photon / methods
Substances
-
Antibodies
-
Antineoplastic Agents
-
Contrast Media
-
Ferric Compounds
-
Magnetite Nanoparticles
-
Peptides
-
Radioisotopes
-
ferric oxide